Now you can have access to even more information about safe medication practices. The U.S. Food and Drug Administration (FDA) has launched a quarterly publication that aims to raise awareness about reported adverse events and to stimulate reporting by health care providers. Topics in the first issue of the FDA Drug Safety Newsletter, released in September 2007, included:
|Figure. No caption available.|
* serious skin reactions associated with modafinil (Provigil), used to treat patients with sleep disorders
* an overview of adverse events associated with deferasirox (Exjade), an oral chelating agent used to treat iron overload due to multiple blood transfusions
* recent FDA drug safety advisories and links for more information.
You can find the newsletter at http://www.fda.gov/cder/dsn/default.htm or subscribe at https://list.nih.gov/cgi-bin/wa?SUBED1=fda-dsn&A=1.